Fujeribio Diagnostics, Inc., based in Japan, has bought Swedish CanAg Diagnostics, merging two leading biotechnology companies in cancer diagnosis.

Microsoft Corp. is spinning out some of its software technology to two small European tech ventures, as part of a program to speed development of innovations from its labs.

A team of researchers at ORNL has come up with the concept of nanofermentation, and, it seems, plans to use this as a trademark.

Europabio thinks that Europe is doing a poor job when it comes to investing in biotechnology.

On May 26, the US Patent Office issued a preliminary ruling on another long-running patent fight. This battle differs from other high-profile clashes as the challenger is taking on not a big corporate entity, but a broad community of IT researchers and academics.

The European Commission wants businesses to spend more on research and development - and to help encourage that, the agency is preparing a volley of government proposals for the Autumn.

The lack of funding from the private sector is still holding back the development of the European biotech sector vis a vis the US despite a similar number of companies in each.

Frost & Sullivan puts some flesh on the bones of the idea that nanotechnology can be a profitable tool in drug development.

Researchers at four European universities are collaborating to develop software that will help encourage the take-up of so called pervasive computing.

European biotech is a hot topic among investors. They have supported as many start-ups as in the US but have seen far from equivalent returns. So what's going on? Science|Business talks to biotechnology consultant John Hodgson.